Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hidracare (also known as Hidracare Solution) is a topical therapeutic solution composed of a salt mixture, developed by Aerotech Australia Pty Ltd. It is specifically targeted for the treatment of hidradenitis suppurativa (HS), a chronic and debilitating inflammatory skin disease characterized by painful nodules and abscesses. The drug is applied topically to affected lesions. Clinical development has included an open-label, single-arm study in Australia focusing on patients with Hurley stage I or II (mild to moderate) HS to assess the product's safety and clinical efficacy over an eight-week period. The precise chemical composition and molecular mechanism of action remain proprietary, though it is intended to alleviate the symptoms of HS through topical administration.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Hidracare.